Is bioAffinity Technologies, Inc. (BIAF) a Buy, Sell, or Hold?
NASDAQ : BIAF
bioAffinity Technologies, Inc.
$0.5297 USD
$0.0 (-0.02%)
- Volume
- 205.15K
- Average Volume
- 381.6K
- Market Capitalization
- $3.33M
- P/E Ratio
- -0.04
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $13.50
- Year Low
- $0.51
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.36
Company Overview
NASDAQ
Maria Zannes
Medical - Diagnostics & Research
Healthcare
BIAF
57
US
USD
Liquidity Metrics
0.38
1.36
1.34
0.97
0.00
Sales & Valuation
$6.16M
0.59
0.65
-0.31
-2.42
Profitability
-$8.66
-$14.91M
-280.57%
-279.95%
-358.76%
-199.87%
P/E Metrics
-0.04
0.00
0.00
Analyst Price Target & Rating
2/5
1 Analysts
%
Financial Health Scores
-18.05
3/9
$1.16M
$7.95M
$4.28M
-$15.8M
Key Metrics (TTM)
$1.61M
0.28
-0.11
1.36
-358.76%
-229.23%
-666.85%
-326.52%
-19 days
Company Executives
| Name | Title |
|---|---|
| Xavier T. Reveles | Chief Operating Officer |
| Gordon Downie | Chief Medical Officer |
| William Bauta | Chief Science Officer |
| Dallas J. Coleman | Vice President of sales |
| James Michael Edwards | Chief Financial Officer |
| Steven Girgenti | Founder & Executive Chairman of the Board |
| Timothy Zannes | Executive Vice President, Secretary & General Counsel |
| Julie Anne Overton | Director of Communications |
| Maria Zannes | Founder, President, Chief Executive Officer & Director |
Poll Results
No votes yet today — be the first to share your view!
About bioAffinity Technologies, Inc. (NASDAQ:BIAF) Stock
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014. ...
2026-07-27 08:08:00
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--BIAF publishes CyPath Lung white paper which presents clinical protocols for lung nodule evaluation, lung cancer patient care & survivor surveillance.
BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
2026-07-24 10:06:10
bioAffinity and Biodesix pursue different cancer diagnostics strategies, but which oncology stock offers better long-term upside? Let's dive in.
2026-07-22 08:08:00
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity and Pictor partner to advance next-generation lung inflammation diagnostics for asthma and COPD for personalized treatment.
2026-07-22 01:23:56
bioAffinity Technologies, Inc. (BIAF) Discusses Innovations in Lung Cancer Screening Technologies for Veterans Transcript
BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell?
2026-07-09 14:37:03
bioAffinity's CyPath Lung sales momentum is gaining traction, but wider losses, funding needs and regulatory risks keep pressure on the stock.
2026-07-07 08:46:00
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technology reports continued acceleration in commercial sales for its CyPath® Lung diagnostic with more than 200% growth year-over-year.
2026-06-22 08:00:00
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies reports on preclinical findings that demonstrate siRNA therapy kills skin cancer cells while sparing healthy cells.
WallachBeth Capital Announces Closing of bioAffinity Technologies $3.2 Million Offering
2026-06-18 14:54:00
JERSEY CITY, N.J., June 18, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, closed its previously announced public offering of securities as described below for aggregate gross proceeds to the Company of $3.2 million, before deducting agent fees and other estimated expenses payable by the company.
Frequently Asked Questions
-
What is the current bioAffinity Technologies, Inc. (BIAF) stock price?
-
bioAffinity Technologies, Inc.(NASDAQ:BIAF) stock price is $0.5297 in the last trading session. During the trading session, BIAF stock reached the peak price of $13.5 while $0.513 was the lowest point it dropped to. The percentage change in BIAF stock occurred in the recent session was --0.02% while the dollar amount for the price change in BIAF stock was -$0.0.
-
BIAF's industry and sector of operation?
-
The NASDAQ listed BIAF is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.
-
Who are the executives of BIAF?
-
Xavier T. Reveles | Chief Operating Officer
Gordon Downie | Chief Medical Officer
William Bauta | Chief Science Officer
Dallas J. Coleman | Vice President of sales
James Michael Edwards | Chief Financial Officer -
How many employees does BIAF have?
-
Number of BIAF employees currently stands at 57. BIAF operates from 3300 Nacogdoches Road, San Antonio, TX 78217, US.
-
Link for BIAF official website?
-
Official Website of BIAF is: https://www.bioaffinitytech.com
-
How do I contact BIAF?
-
BIAF could be contacted at phone #210 698 5334 and can also be accessed through its website. BIAF operates from 3300 Nacogdoches Road, San Antonio, TX 78217, US.
-
How many shares of BIAF are traded daily?
-
The average number of BIAF shares traded daily for last 3 months was 381.6K.
-
What is the market cap of BIAF currently?
-
The market value of BIAF currently stands at $3.33M with its latest stock price at $0.5297